Severe illness associated with synthetic cannabinoid use - Brunswick, Georgia, 2013

Morbidity and Mortality Weekly Report

Volumn 62, Issue 46, 2013, Pages 939-

  Drenzek, Cherie ^a   Geller, Robert J ^b   Steck, Alaina ^b   Arnold, Justin ^b   Lopez, Gaylord ^b   Gerona, Roy ^c   Edison, Laura ^d  

^a GEORGIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b Georgia Poison Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888104990     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Uchiyama N, Kawamura M, Kikura-Hanajiri R, et al. Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 2012;30:114-25.
2. Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011;5:60.
3. CDC. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR 2013;62:93-8.
4. Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 2011;49:760-4.